268 related articles for article (PubMed ID: 28482391)
41. Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression.
Gilmour KC; Cranston T; Jones A; Davies EG; Goldblatt D; Thrasher A; Kinnon C; Nichols KE; Gaspar HB
Eur J Immunol; 2000 Jun; 30(6):1691-7. PubMed ID: 10898506
[TBL] [Abstract][Full Text] [Related]
42. Study of SH2D1A gene mutation in paediatric patients with B-cell lymphoma.
Koochakzadeh L; Hosseinverdi S; Hedayat M; Farahani F; Tofighi A; Eghbali M; Bidoki AZ; Izadyar M; Rahiminejad MS; Ramyar A; Aghamohammadi A; Rezaei N
Allergol Immunopathol (Madr); 2015; 43(6):568-70. PubMed ID: 25982576
[TBL] [Abstract][Full Text] [Related]
43. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase.
Aoukaty A; Tan R
J Biol Chem; 2002 Apr; 277(15):13331-7. PubMed ID: 11815622
[TBL] [Abstract][Full Text] [Related]
44. X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.
Panchal N; Booth C; Cannons JL; Schwartzberg PL
Front Immunol; 2018; 9():666. PubMed ID: 29670631
[TBL] [Abstract][Full Text] [Related]
45. Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Naïve Boy Is Associated With a Novel
Steininger J; Rossmanith R; Geier CB; Leiss-Piller A; Thonhauser L; Weiss S; Hainfellner JA; Freilinger M; Schmidt WM; Eibl MM; Wolf HM
Front Immunol; 2021; 12():747738. PubMed ID: 34987501
[TBL] [Abstract][Full Text] [Related]
46. SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients.
Sanzone S; Zeyda M; Saemann MD; Soncini M; Holter W; Fritsch G; Knapp W; Candotti F; Stulnig TM; Parolini O
J Biol Chem; 2003 Aug; 278(32):29593-9. PubMed ID: 12766168
[TBL] [Abstract][Full Text] [Related]
47. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells.
Ma CS; Hare NJ; Nichols KE; Dupré L; Andolfi G; Roncarolo MG; Adelstein S; Hodgkin PD; Tangye SG
J Clin Invest; 2005 Apr; 115(4):1049-59. PubMed ID: 15761493
[TBL] [Abstract][Full Text] [Related]
48. Lymphocytic vasculitis in X-linked lymphoproliferative disease.
Dutz JP; Benoit L; Wang X; Demetrick DJ; Junker A; de Sa D; Tan R
Blood; 2001 Jan; 97(1):95-100. PubMed ID: 11133747
[TBL] [Abstract][Full Text] [Related]
49. X-linked lymphoproliferative disease: three atypical cases.
Nistala K; Gilmour KC; Cranston T; Davies EG; Goldblatt D; Gaspar HB; Jones AM
Clin Exp Immunol; 2001 Oct; 126(1):126-30. PubMed ID: 11678908
[TBL] [Abstract][Full Text] [Related]
50. [Clinical and gene research of X-linked lymphoproliferative disease in a Chinese family].
Zhu DX; Du J; Lan HK; Yu L; Feng ZC
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):244-8. PubMed ID: 17425868
[TBL] [Abstract][Full Text] [Related]
51. Genomic organization and characterization of mouse SAP, the gene that is altered in X-linked lymphoproliferative disease.
Wu C; Sayos J; Wang N; Howie D; Coyle A; Terhorst C
Immunogenetics; 2000 Aug; 51(10):805-15. PubMed ID: 10970095
[TBL] [Abstract][Full Text] [Related]
52. Potential pathogenic mechanism of type 1 X-linked lymphoproliferative syndrome caused by a mutation of SH2D1A gene in an infant: A case report.
Wang Y; Wang Y; Lu W; Tao L; Xiao Y; Zhou Y; He X; Zhang Y; Li L
Medicine (Baltimore); 2022 Oct; 101(41):e30951. PubMed ID: 36254040
[TBL] [Abstract][Full Text] [Related]
53. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency.
Marsh RA; Bleesing JJ; Filipovich AH
J Immunol Methods; 2010 Oct; 362(1-2):1-9. PubMed ID: 20816973
[TBL] [Abstract][Full Text] [Related]
54. Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines.
Kis LL; Nagy N; Klein G; Klein E
Int J Cancer; 2003 May; 104(5):658-61. PubMed ID: 12594824
[TBL] [Abstract][Full Text] [Related]
55. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene.
Arico M; Imashuku S; Clementi R; Hibi S; Teramura T; Danesino C; Haber DA; Nichols KE
Blood; 2001 Feb; 97(4):1131-3. PubMed ID: 11159547
[TBL] [Abstract][Full Text] [Related]
56. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome.
Morra M; Silander O; Calpe S; Choi M; Oettgen H; Myers L; Etzioni A; Buckley R; Terhorst C
Blood; 2001 Sep; 98(5):1321-5. PubMed ID: 11520777
[TBL] [Abstract][Full Text] [Related]
57. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
58. Epstein-Barr virus (EBV) and X-linked lymphoproliferative syndrome (XLP).
Tatsumi E; Purtilo DT
AIDS Res; 1986 Dec; 2 Suppl 1():S109-13. PubMed ID: 3030340
[TBL] [Abstract][Full Text] [Related]
59. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma.
Rezaei N; Mahmoudi E; Aghamohammadi A; Das R; Nichols KE
Br J Haematol; 2011 Jan; 152(1):13-30. PubMed ID: 21083659
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
